Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Investing.com - BofA Securities initiated coverage on Vera Therapeutics (NASDAQ:VERA) with a Buy rating and a price target of $48.00 on Thursday. According to InvestingPro data, analyst targets for VERA range from $23 to $100, with the stock currently trading at $31.
The research firm views potential upside in VERA shares coming from its lead drug, atacicept, which is being developed for autoimmune conditions and could enter what BofA describes as a multibillion-dollar market.
BofA Securities believes atacicept could exceed current market consensus expectations and address concerns about competitive risks in the autoimmune treatment space.
The firm also noted that Vera’s life cycle management efforts could potentially yield an improved drug profile, which would support further stock appreciation beyond their current price target.
BofA Securities considers Vera’s current valuation attractive, noting the stock has fallen 38% year-to-date, positioning it favorably ahead of what the firm identifies as key catalysts expected in the fourth quarter of 2025 and beyond. While the stock shows strong momentum with a 46% gain over the past six months, InvestingPro analysis suggests the stock is currently trading near its Fair Value, with 12 additional exclusive insights available to subscribers.
In other recent news, Vera Therapeutics has been the focus of differing analyst opinions. Cantor Fitzgerald reiterated its Overweight rating for the company, maintaining a price target of $100.00. This optimistic outlook is largely due to Vera’s drug candidate, atacicept, which has received Breakthrough Designation status for treating IgA nephropathy. Vera Therapeutics plans to file a Biologics License Application for atacicept this quarter, which could significantly impact its future operations. On the other hand, Wolfe Research downgraded Vera Therapeutics from Outperform to Peerperform. This decision was based on the company’s limited catalysts and a notable 57% decline in its stock since November. Wolfe Research pointed out that Vera Therapeutics has not seen a share price recovery even though the broader biotech sector experienced a rally in June. These recent developments highlight the mixed sentiments surrounding Vera Therapeutics’ potential growth and challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.